Granules India Limited has officially communicated the record date for its final dividend distribution for the financial year ended March 31, 2026. The pharmaceutical company sent formal intimation to stock exchanges on April 29, 2026, setting July 30, 2026 as the crucial date for dividend eligibility.

Official Record Date Communication

The company has established the following parameters for its dividend distribution through official regulatory communication:

Regulatory Compliance Framework

The announcement was made in strict compliance with Regulation 42 of the Securities & Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. This regulation mandates listed companies to inform stock exchanges about record dates for corporate actions, including dividend distributions.

The formal communication was addressed to both National Stock Exchange India Limited and BSE Limited, where Granules India shares are traded under scrip codes NSE-GRANULES and BSE-532482 respectively.

Digital Authentication and Authorization

Chaitanya Tummala, Company Secretary & Compliance Officer, digitally signed the official communication on April 29, 2026 at 14:11:19 +05'30'. The document carries the official blue circular stamp of Granules India Limited, Hyderabad, ensuring authenticity and regulatory compliance.

Shareholder Eligibility Criteria

Shareholders holding Granules India Limited shares on the record date of July 30, 2026 will be eligible to receive the final dividend for FY26. This cut-off date determines dividend entitlement based on registered shareholding as per company records on the specified date.

Corporate Information

Granules India Limited operates under CIN: L24110TG1991PLC012471 with its registered office located at 15th Floor, Granules Tower, Botanical Garden Road, Kondapur, Hyderabad – 500084, Telangana. The company maintains corporate communication through official channels including Tel: +91 40 69043500 and email: mail@granulesindia.com .

Granules India has announced its audited financial results for the fourth quarter and financial year ended March 31, 2026, demonstrating solid performance across key metrics. The Board of Directors approved the standalone and consolidated results at their meeting held on April 29, 2026, with statutory auditors M/s. S R Batliboi & Associates LLP issuing an unmodified opinion on the financial statements.

Consolidated Financial Performance

The company's consolidated financial results for FY26 showed significant improvement in profitability. Net profit for the year increased 18.7% to ₹5,950.21 million from ₹5,015.16 million in the previous year. For Q4 FY26, net profit stood at ₹2,015.68 million compared to ₹1,520.31 million in the corresponding quarter of the previous year.

Total revenue from operations for FY26 reached ₹53,656.42 million, representing a 19.8% growth from ₹44,816.08 million in FY25. Q4 FY26 revenue stood at ₹14,706.08 million compared to ₹11,974.29 million in Q4 FY25.

Operational Efficiency and Margins

The company's operational metrics demonstrated improvement during the year. EBITDA for Q4 surged 39.7% year-over-year to ₹3,520 million from ₹2,520 million, indicating enhanced operational efficiency. The EBITDA margin expansion to 24.16% from 21.07% represents an improvement of over 300 basis points, reflecting the company's focus on operational excellence.

Key Developments and Strategic Initiatives

During FY26, Granules India completed significant strategic acquisitions. Senn Chemicals AG became a wholly owned step-down subsidiary effective April 10, 2025, following a Share Purchase Agreement signed on February 21, 2025. Additionally, the company acquired a 100% equity stake in Granules Pharmaceuticals GmbH (formerly Optus 1039 GmbH), Germany for EUR 28,400 on November 20, 2025. A new subsidiary, Granules Pharmaceuticals Canada, Inc., was incorporated on November 26, 2025.

The Board recommended a final dividend of ₹1.75 per equity share of ₹1 each. Furthermore, the company issued 25,000,000 warrants on a preferential basis at ₹585 per warrant, receiving ₹3,656.25 million as 25% of the total consideration on February 23, 2026.

Balance Sheet Strength

The consolidated balance sheet as of March 31, 2026, showed total assets of ₹77,199.50 million compared to ₹62,525.61 million in the previous year. Total equity increased to ₹50,849.95 million from ₹37,155.78 million, while total liabilities stood at ₹26,349.55 million. Cash and cash equivalents improved significantly to ₹8,802.38 million from ₹4,661.14 million at the end of FY25.